

## **Pegasys® supply update 14 July 2025**

Dear New Zealand Clinicians and Patients

As you are aware, we have been navigating our constrained supplies of Pegasys® over the last 10 months due to the change in manufacturing site and limited allocations during the global shortage. Please share this updated communication with all relevant Healthcare Professionals.

### **Current status (July 2025) of the New Zealand (NZ) labelled Pegasys® 180 mcg**

As of Monday 14th July 2025, we have limited stock of the Pegasys® 180 mcg presentation. This is being managed under the 'scarce supply' process, and orders are individually released for patients as indicated by retail and hospital pharmacies across NZ via their respective wholesalers.

The timelines continue to evolve as Echo Therapeutics does not have confirmed dates of future supplies and changes in the short term are challenging to predict.

### **Approval of the Austrian manufacturing facility**

We have some good news to share: the new manufacturing facility in Austria has been approved and has begun manufacturing. This means we will start to receive Australian & New Zealand labelled stock later this year. At this stage the timeline we have been given is **November 2025**. The challenge is finding a solution for the supply interruption until the new NZ stock arrives in November.

### **Section 29: PHARMAC has approved funding for Irish-labelled stock of 180 mcg Pegasys® during the shortage:**

Additionally, we have successfully negotiated with Pharma& (the owners of Pegasys®) to secure some European product, specifically Irish-labelled stock, for NZ patients. The teams at Echo Therapeutics and Pharma& have worked with the PHARMAC to get special approval to allow this stock to be funded for patients across New Zealand via the Section 29 pathway which allows for unregistered stock to be used locally. This Irish labelled Pegasys® is manufactured at the new Austrian plant, and, other than the labelling, will be identical in formulation to the NZ stock planned for supply from November, i.e. it will meet the Regulatory requirements of Medsafe.

The Irish labelled stock is expected to arrive in late July 2025. The Pharmacode for this product is 2706768, effective from July 1, 2025.

NOTE: Please continue to use current code until the NZ labelled stock is exhausted.

**Your crucial support and patience is much appreciated as we navigate the S29 Irish labelled stock during the shortage, and through to resumption of full supply.**

With your help and support, we can initially look to utilise the current remaining 180 mcg NZ stock. This will be followed by the Irish-labelled stock scheduled for supply from late July 2025.

Please note, this has been an evolving situation and Echo Therapeutics has lobbied with the manufacturer very diligently to secure Pegasys® for New Zealand patients. The situation in some countries in Europe and other parts of the world has been more dire with supply interruptions for many months. Nonetheless, while we have a near-term solution, we will still be faced with challenges which may require clinicians and patients to explore dosing and management strategies for individual needs.

Supply of the Irish labelled stock will be released to wholesalers in a controlled manner, to prevent stockpiling and mitigate the risk of unapproved export, which has happened in Australia and other parts of the globe.

**What happens when Echo resumes supply of New Zealand labelled stock later this year?**

It is important to note, that once supply of the new NZ labelled Pegasys® recommences (expected November 2025), Echo intends to continue servicing patients via relevant wholesalers, allocating and monitoring stock levels until **consistent** supply is established. We commit to our continued transparent communication during this period.

Echo Therapeutics appreciates your support through this period as the quantity, timing and scheduling of deliveries of New Zealand labelled stock continues to evolve. This results from all countries globally requiring a build-up of stock to a level that is efficient and equitable, for all patients worldwide.

Thank you for your understanding, your resilience and continuing to help us manage these changes as they come to light. The team at Echo Therapeutics has been doing a lot of work behind the scenes to secure stock, the aim being to ensure equitable supply and avoid patients going without this critical medicine.

Please also see a short video with Haematologist, Dr Cecily Forsyth (Australia) and Nathalie Cook OAM, from the patient advocacy group Myeloproliferative Neoplasms Alliance Australia (MPNAA) about some suggested treatment strategies to consider.

<https://www.mpnallianceaustralia.org.au/video-interview-re-pegasys-supply/>

(Please note there may be reference to a Home Delivery Program and a 135mcg presentation which is not currently available in NZ).

Warm regards

**Jude**

Jude D'Silva  
Managing Director  
Echo Therapeutics  
Website: [www.echotherapeutics.com.au](http://www.echotherapeutics.com.au)